文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

70 岁及以上老年直肠癌患者接受放疗或放化疗的耐受性和结局。

Tolerability and outcomes of radiotherapy or chemoradiotherapy for rectal cancer in elderly patients aged 70 years and older.

机构信息

Department of Radiological Oncology, Fudan University Shanghai Cancer Center, 270 Dong'An Road, Shanghai 200032, People's Republic of China.

出版信息

Radiat Oncol. 2013 Apr 10;8:86. doi: 10.1186/1748-717X-8-86.


DOI:10.1186/1748-717X-8-86
PMID:23574985
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3641029/
Abstract

PURPOSE: To assess the safety and outcomes of radiotherapy (RT) or chemoradiotherapy (CRT) in elderly patients (≥70) with rectal cancer. METHODS: Elderly patients aged 70 and older with rectal cancer, who were treated with RT or CRT at a single institution, were retrospectively analyzed. Performance status (KPS and ECOG score) and comorbidity (Charlson comorbidity index) were calculated, and their correlation with treatment toxicity and overall survival were studied. Risk factors for overall survival were investigated using univariate and multivariate survival analysis. RESULTS: A total of 126 patients with locally advanced disease, local recurrence or synchronous metastasis were included, with a 3-year OS rate of 48.1%. Scheduled dosage of radiation was delivered to 69% of patients. Grade 3 toxicities occurred more often in patients treated with CRT versus RT. The occurrence of grade 3 toxicities was not related to KPS score, ECOG score, number of comorbidities, and Charlson score. Multivariate analysis found that only age and Charlson score were independent prognostic factors for predicting patients' 3-year OS. The 3-year OS rate was significantly higher in patients with Charlson score <4 vs Charlson score ≥4 (71.1% vs. 26.4%, P=0.0003). CONCLUSIONS: Although toxicities may be significant, elderly patients with rectal cancer of varied stages can be safely treated with RT or CRT with careful monitoring and frequent modification of treatment. Except for patients' age, Charlson comorbidity index may be helpful in assessing patients' outcomes in elderly patients with rectal cancer.

摘要

目的:评估放疗(RT)或放化疗(CRT)在老年(≥70 岁)直肠癌患者中的安全性和结局。

方法:回顾性分析了在单一机构接受 RT 或 CRT 治疗的年龄≥70 岁的老年直肠癌患者。计算了患者的体能状态(KPS 和 ECOG 评分)和合并症(Charlson 合并症指数),并研究了它们与治疗毒性和总生存的相关性。使用单因素和多因素生存分析研究了总生存的危险因素。

结果:共纳入 126 例局部晚期疾病、局部复发或同步转移的患者,3 年 OS 率为 48.1%。69%的患者接受了计划剂量的放疗。与 RT 相比,接受 CRT 治疗的患者更常出现 3 级毒性。3 级毒性的发生与 KPS 评分、ECOG 评分、合并症数量和 Charlson 评分无关。多因素分析发现,只有年龄和 Charlson 评分是预测患者 3 年 OS 的独立预后因素。Charlson 评分<4 的患者 3 年 OS 率明显高于 Charlson 评分≥4 的患者(71.1% vs. 26.4%,P=0.0003)。

结论:尽管毒性可能很明显,但患有不同阶段直肠癌的老年患者可以在密切监测和频繁调整治疗的情况下安全地接受 RT 或 CRT 治疗。除了患者的年龄,Charlson 合并症指数可能有助于评估老年直肠癌患者的预后。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/46f6/3641029/680007cfedbb/1748-717X-8-86-2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/46f6/3641029/bca1c3bb6eb8/1748-717X-8-86-1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/46f6/3641029/680007cfedbb/1748-717X-8-86-2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/46f6/3641029/bca1c3bb6eb8/1748-717X-8-86-1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/46f6/3641029/680007cfedbb/1748-717X-8-86-2.jpg

相似文献

[1]
Tolerability and outcomes of radiotherapy or chemoradiotherapy for rectal cancer in elderly patients aged 70 years and older.

Radiat Oncol. 2013-4-10

[2]
Is the Charlson Comorbidity Index a Prognostic Indicator for Toxicity and Mortality in Elderly Patients with Locally Advanced Rectal Cancer?

Arch Iran Med. 2019-5-1

[3]
Preoperative Chemoradiotherapy for Rectal Cancer in Patients Aged 75 Years and Older: Acute Toxicity, Compliance with Treatment, and Early Results.

Drugs Aging. 2016-6

[4]
Clinical outcomes in elderly rectal cancer patients treated with neoadjuvant chemoradiotherapy: impact of tumor regression grade : Tumor regression grade after neoadjuvant chemoradiotherapy in elderly rectal cancer patients.

J Cancer Res Clin Oncol. 2021-4

[5]
Severe weight loss during preoperative chemoradiotherapy compromises survival outcome for patients with locally advanced rectal cancer.

J Cancer Res Clin Oncol. 2016-12

[6]
Preoperative chemoradiotherapy for elderly patients with locally advanced rectal cancer-a real-world outcome study.

Jpn J Clin Oncol. 2016-12

[7]
Outcomes of neoadjuvant chemoradiotherapy followed by total mesorectal excision surgery for locally advanced rectal cancer: a single-institution experience.

Singapore Med J. 2018-6

[8]
Feasibility and efficacy of chemoradiotherapy for elderly patients with locoregionally advanced nasopharyngeal carcinoma: results from a matched cohort analysis.

Radiat Oncol. 2013-3-22

[9]
Preoperative chemoradiotherapy improves local recurrence free survival in locally advanced rectal cancer.

J BUON. 2013

[10]
Tolerability of combined modality therapy for rectal cancer in elderly patients aged 75 years and older.

Int J Radiat Oncol Biol Phys. 2011-3-4

引用本文的文献

[1]
Prognostic Value of Pretreatment Carcinoembryonic Antigen (CEA) in Rectal Cancer Treated with Preoperative Short-Course Radiotherapy with Delayed Surgery or Long-Course Radiotherapy.

Onco Targets Ther. 2025-1-16

[2]
Comprehensive geriatric assessment guided radiotherapy in elderly patients with locally advanced rectal cancer-exploratory results on nonoperative cohort of a multicenter prospective study.

Ther Adv Med Oncol. 2024-11-19

[3]
Comparison of Selected Older and Younger Patients Regarding Optimal Surgical Treatment of Colorectal Cancer: A Prospective Cohort Study.

Cancer Diagn Progn. 2023-7-3

[4]
The Impact of Age in the Treatment of Non-comorbid Patients with Rectal Cancer: Survival Outcomes from the National Cancer Database.

World J Surg. 2023-8

[5]
Non-stereotactic radiotherapy in older cancer patients.

Heliyon. 2022-5-31

[6]
Toxicities and outcomes of neoadjuvant treatment in elderly patients with locally advanced rectal cancer: a scoping review protocol.

BMJ Open. 2022-5-2

[7]
Current Treatment Approaches and Outcomes in the Management of Rectal Cancer Above the Age of 80.

Curr Oncol. 2021-3-30

[8]
Clinical outcomes in elderly rectal cancer patients treated with neoadjuvant chemoradiotherapy: impact of tumor regression grade : Tumor regression grade after neoadjuvant chemoradiotherapy in elderly rectal cancer patients.

J Cancer Res Clin Oncol. 2021-4

[9]
Worse treatment response to neoadjuvant chemoradiotherapy in young patients with locally advanced rectal cancer.

BMC Cancer. 2020-9-5

[10]
Worse prognosis in young patients with locally advanced rectal cancer following neoadjuvant chemoradiotherapy: A comparative study.

Medicine (Baltimore). 2020-8-28

本文引用的文献

[1]
Effect of adjuvant chemotherapy on survival of patients with stage III colon cancer diagnosed after age 75 years.

J Clin Oncol. 2012-6-4

[2]
Safety and outcome of chemoradiotherapy in elderly patients with rectal cancer: results from two French tertiary centres.

Dig Liver Dis. 2011-11-25

[3]
Tolerability of combined modality therapy for rectal cancer in elderly patients aged 75 years and older.

Int J Radiat Oncol Biol Phys. 2011-3-4

[4]
The effect of comorbidity on the use of adjuvant chemotherapy and survival from colon cancer: a retrospective cohort study.

BMC Cancer. 2009-4-20

[5]
Half of elderly patients routinely treated for colorectal cancer receive a sub-standard treatment.

Crit Rev Oncol Hematol. 2009-9

[6]
Predicting in-hospital mortality in patients with cirrhosis: results differ across risk adjustment methods.

Hepatology. 2009-2

[7]
Survival of elderly rectal cancer patients not improved: analysis of population based data on the impact of TME surgery.

Eur J Cancer. 2007-10

[8]
Are we undertreating rectal cancer in the elderly? An epidemiologic study.

Ann Surg. 2007-8

[9]
Comprehensive geriatric assessment for older patients with cancer.

J Clin Oncol. 2007-5-10

[10]
Chemotherapy with preoperative radiotherapy in rectal cancer.

N Engl J Med. 2006-9-14

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索